The factors contributing to crizotinib-induced ILD in ROS1-positive patients remain unclear, whereas risk factors significantly correlated with the development of ILD in ALK-positive NSCLC patients have been described and include age, poor performance status, smoking status, past/concomitant ILD and concomitant pleural effusion [5]. Here, ROS1 is linked to interstitial lung disease.